Cargando…
Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis
BACKGROUND: The treatment of hepatitis C virus (HCV) in HCV/human immunodeficiency virus (HIV) co-infected patients remains complex. This present meta-analysis evaluated the efficacy and safety of Sofosbuvir (SOF) for treatment in HCV/HIV co-infected patients using the most recent and available data...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775578/ https://www.ncbi.nlm.nih.gov/pubmed/29351766 http://dx.doi.org/10.1186/s12985-018-0934-6 |
_version_ | 1783293939265044480 |
---|---|
author | Li, Guotao Zang, Ke Zhang, Guoqiang Zhu, Danyan Deng, Xiaozhao |
author_facet | Li, Guotao Zang, Ke Zhang, Guoqiang Zhu, Danyan Deng, Xiaozhao |
author_sort | Li, Guotao |
collection | PubMed |
description | BACKGROUND: The treatment of hepatitis C virus (HCV) in HCV/human immunodeficiency virus (HIV) co-infected patients remains complex. This present meta-analysis evaluated the efficacy and safety of Sofosbuvir (SOF) for treatment in HCV/HIV co-infected patients using the most recent and available data. METHODS: A systematic search of the published data was conducted in PubMed Medline, EMBASE and Cochrane databases. Eligible studies were clinical trials, case-control studies or prospective cohort studies aiming at assessing the efficacy and safety of the SOF-containing regimens in patients co-infected with HCV and HIV. Heterogeneity of results was assessed and a pooled analysis was performed using random effects model with maximum likelihood estimate and 95% confidence intervals (95%CI). Subgroup analysis and assessment of publication bias through Egger’s test were also performed. STATA 13.0 software was used to analyze the data. RESULTS: Seven studies (n = 1167 co-infected patients) were included in this analysis. The pooled estimate of sustained virological response at 12 weeks (SVR12) was 94.0% (95%CI: 92.0%–95.0%). Subgroup analysis showed that the treatment-naïve patients had higher SVR12 compared with patients that were treated before (χ(2) = 21.39, P < 0.01). The pooled incidence of any adverse events (AEs) was 79.6% (95%CI: 77.1%–82.1%). Publication bias did not exist. CONCLUSION: The results of this study showed that the treatment response of SOF-containing regimens in patients co-infected with HIV and HCV was satisfied. Attention should be paid to the high rates of AEs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-018-0934-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5775578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57755782018-01-31 Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis Li, Guotao Zang, Ke Zhang, Guoqiang Zhu, Danyan Deng, Xiaozhao Virol J Research BACKGROUND: The treatment of hepatitis C virus (HCV) in HCV/human immunodeficiency virus (HIV) co-infected patients remains complex. This present meta-analysis evaluated the efficacy and safety of Sofosbuvir (SOF) for treatment in HCV/HIV co-infected patients using the most recent and available data. METHODS: A systematic search of the published data was conducted in PubMed Medline, EMBASE and Cochrane databases. Eligible studies were clinical trials, case-control studies or prospective cohort studies aiming at assessing the efficacy and safety of the SOF-containing regimens in patients co-infected with HCV and HIV. Heterogeneity of results was assessed and a pooled analysis was performed using random effects model with maximum likelihood estimate and 95% confidence intervals (95%CI). Subgroup analysis and assessment of publication bias through Egger’s test were also performed. STATA 13.0 software was used to analyze the data. RESULTS: Seven studies (n = 1167 co-infected patients) were included in this analysis. The pooled estimate of sustained virological response at 12 weeks (SVR12) was 94.0% (95%CI: 92.0%–95.0%). Subgroup analysis showed that the treatment-naïve patients had higher SVR12 compared with patients that were treated before (χ(2) = 21.39, P < 0.01). The pooled incidence of any adverse events (AEs) was 79.6% (95%CI: 77.1%–82.1%). Publication bias did not exist. CONCLUSION: The results of this study showed that the treatment response of SOF-containing regimens in patients co-infected with HIV and HCV was satisfied. Attention should be paid to the high rates of AEs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-018-0934-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-19 /pmc/articles/PMC5775578/ /pubmed/29351766 http://dx.doi.org/10.1186/s12985-018-0934-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Li, Guotao Zang, Ke Zhang, Guoqiang Zhu, Danyan Deng, Xiaozhao Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis |
title | Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis |
title_full | Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis |
title_fullStr | Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis |
title_full_unstemmed | Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis |
title_short | Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis |
title_sort | efficacy and safety of sofosbuvir-containing regimens in patients co-infected with chronic hepatitis c virus and human immunodeficiency virus: a meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775578/ https://www.ncbi.nlm.nih.gov/pubmed/29351766 http://dx.doi.org/10.1186/s12985-018-0934-6 |
work_keys_str_mv | AT liguotao efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis AT zangke efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis AT zhangguoqiang efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis AT zhudanyan efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis AT dengxiaozhao efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis |